Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in Care
Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
NSCLC: Treatment Options for Patients With Driver Mutations and PD-L1 Expression
Closing out their review of the second patient scenario, panelists define treatment options for NSCLC with both EGFR mutation and PD-L1 expression.
Chart Review 2: A 73-Year-Old Asian Woman With Advanced NSCLC
Expert oncologists consider how they would approach molecular testing in a 73-year-old Asian woman diagnosed with advanced non–small cell lung cancer.
Selecting Second-Line Treatment for EGFR-Mutated Advanced NSCLC
Focusing on second-line treatment options for EGFR-mutated advanced NSCLC, panelists review the use of mobocertinib and amivantamab, respectively.
Selecting First-Line Treatment for EGFR-Mutated Advanced NSCLC
Experts briefly reflect on optimal frontline treatment strategies for a patient who presents with EGFR-mutated advanced non–small cell lung cancer.
Chart Review 1: A 57-Year-Old Man With Advanced NSCLC
Centering discussion on a 57-year-old man with advanced NSCLC, panelists consider molecular testing strategies and the subsets of EGFR mutation.
Improving Care in NSCLC: Patient Education Strategies
A brief reflection on optimal patient education strategies, specifically regarding biomarker testing, in the setting of non–small cell lung cancer.
Optimizing Molecular Testing in Patients With Non-Small Cell Lung Cancer
Closing out their discussion on NSCLC biomarker testing assay selection, panelists consider the optimal use of these assays in their own patients.
Molecular Testing Assays in Non-Small Cell Lung Cancer
Expert oncologists provide a comprehensive review of available biomarker testing assays utilized in patients diagnosed with non–small cell lung cancer.
2 Commerce Drive Cranbury, NJ 08512